Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 April 2003 | Volume 138 Issue 7 | Pages 576-580
The technology of molecular genetics has profoundly altered the conduct of biomedical research. An entire universe of problems that in the past had been addressed only through conjecture, including whole genome analysis, can now be studied directly. The rapidity and scope of these changes in research capacity have in turn led to speculation that medicine will be radically altered by the application of genomics to everyday practice. To date, gene therapy and several new tests for genetic susceptibility have been successfully implemented, although their impact on medicine as a whole remains very limited and their future contribution is hotly contested. The potential of molecular genetics, like all technology, must be evaluated on the basis of established principles of clinical and epidemiologic research. The rhetoric of some enthusiasts focuses instead on an optimistic best-case scenario of the future of DNA science, and many of their most far-reaching claims cannot be substantiated on the basis of what is currently known. The tension between the long-term goal of public health and medicine to identify and remove the causes of ill health, in contrast to the development of technological innovations that can cure disease or identify individual susceptibility, emerges as a major theme in this debate.
Author and Article Information
From Loyola Stritch School of Medicine, Maywood, Illinois, and University of Washington, Seattle, Washington.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Richard C. Cooper, MD, Department of Preventive Medicine and Epidemiology, Loyola Stritch School of Medicine, 2160 South First Avenue, Maywood, IL 60153; e-mail, rcooper{at}lumc.edu.
Current Author Addresses: Dr. Cooper: Department of Preventive Medicine and Epidemiology, Loyola Stritch School of Medicine, 2160 South First Avenue, Maywood, IL 60153.
Dr. Psaty: Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, 1730 Minor Avenue, Suite #1360, University of Washington, Seattle, WA 98101. PERSPECTIVE
Genomics and Medicine: Distraction, Incremental Progress, or the Dawn of a New Age?
![]()
This article has been cited by other articles:
![]() |
S. I. Brandt-Rauf, V. H. Raveis, N. F. Drummond, J. A. Conte, and S. M. Rothman Ashkenazi Jews and Breast Cancer: The Consequences of Linking Ethnic Identity to Genetic Disease Am J Public Health, November 1, 2006; 96(11): 1979 - 1988. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Li, R. M. Canham, W. Vongpatanasin, D. Leonard, R. J. Auchus, and R. G. Victor Do Allelic Variants in {alpha}2A and {alpha}2C Adrenergic Receptors Predispose to Hypertension in Blacks? Hypertension, June 1, 2006; 47(6): 1140 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Billings, R. J. Carlson, J. Carlson, M. Cain, C. Wilson, P. Shorett, and W. Everett Ready for Genomic Medicine? Perspectives of Health Care Decision Makers Arch Intern Med, September 12, 2005; 165(16): 1917 - 1919. [Full Text] [PDF] |
||||
![]() |
M. J. Khoury, R. Davis, M. Gwinn, M. L. Lindegren, and P. Yoon Do We Need Genomic Research for the Prevention of Common Diseases with Environmental Causes? Am. J. Epidemiol., May 1, 2005; 161(9): 799 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Mohrenweiser Genetic Variation and Exposure Related Risk Estimation: Will Toxicology Enter a New Era? DNA Repair and Cancer as a Paradigm Toxicol Pathol, January 1, 2004; 32(1_suppl): 136 - 145. [Abstract] [PDF] |
||||